VRAX

distress 5/10 · elevated risk

$3.49-4%today-87% from 52w high

viraxbiolabs.com26 employeesFounded 2013Lanarkshire, United KingdomBiotechnology

Revenue

pre-revenue

Liquidity

$6M

Runway

1.4 yrs

Shares 1y

Price & events

-48.7% over 6M

CatalystRating changeDilutionFinancingdashed = today

-4.1%

-10.5%

-9.9%

-12.2%

-46.9%

-86.0%

-88.2%

—

-99.9%

All

Overview

Market Cap: $2.02M
Volume: 17.59K
52 Week Range: $2.60 – $27.75
Total Shares: 579.22K
Float Shares: 529.03K
Short %: 7.78%
% Held by Insiders: 2.62%
% Held by Institutions: 4.61%
RVOL: 0.01x
Beta: 1.33

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Catalyst news & presentations · 0

No catalyst news yet.

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 579,218 · 1 offerings/1y · 0 PIPEs

2025-12-31424B3offering
2025-12-30EFFECTshelf_effective
2025-12-18F-3shelf_registration
2024-11-14SC 13G/Astrategic_stake
2024-09-30424B5offering
2024-08-23424B5offering

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

no consensus

2026-01-09HC Wainwright & Co.Buy
2025-03-31HC Wainwright & Co.Buy

Competitors

none identified